<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797156</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 19-1137</org_study_id>
    <nct_id>NCT04797156</nct_id>
  </id_info>
  <brief_title>Combined IV and Topical TXA in Major Spine Surgery</brief_title>
  <official_title>The Effect of Combined Intravenous and Topical TXA in Major Multilevel Spine Surgery: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study. The purpose of this study is to evaluate the effect of tranexamic&#xD;
      acid in patients undergoing multilevel spine surgery. 75 patients undergoing multi-level&#xD;
      spine surgery will be enrolled at Mount Sinai West. Study participation will last from the&#xD;
      time of pre-operative evaluation to the time of discharge from hospital. Specifically, the&#xD;
      study team will compare tranexamic acid given only intravenously vs. given both topically and&#xD;
      intravenously vs. given only intravenously but at a higher dosage. The study team&#xD;
      hypothesizes that patient who received combined topical and intravenous TXA (low dose) have&#xD;
      similar or decreased overall blood loss postoperatively compared to patient who received high&#xD;
      or low dose intravenous TXA alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective triple-blinded randomized control trial. The surgeon will provide study&#xD;
      information (protocol, consent, general information) to patients in the surgeon's office.&#xD;
      Recruitment will be done through a coordination of the operating schedule and the surgeon's&#xD;
      office. Patients presenting for preoperative visits at the surgeon's office or the&#xD;
      preoperative joint clinic will be approached. On the day of the surgery, the subject will&#xD;
      meet the research team in the holding area. The team will finalize participation and ask the&#xD;
      subject about the signed consent forms and answer any additional questions. All patients will&#xD;
      be provided with copies of the IRB protocol and consent if they wish to have it. Copy of the&#xD;
      consent form will be sent in a secured email to the potential subject. The email will be&#xD;
      secured by entering in [SECURE] in the e-mail subject line. Once recruited blinding&#xD;
      assessments will be done by the study team.&#xD;
&#xD;
      Patients will be assigned randomly using a computer-generated table of numbers to one of the&#xD;
      three groups: 1) High Dose Intravenous TXA (hTXA group), 2) Low Dose Intravenous TXA (lTXA&#xD;
      group), or 3) Combined Intravenous and Topical TXA group (cTXA group). Surgical team will&#xD;
      perform the required spine procedure. Study personnel will make the medication which will be&#xD;
      labelled as study drug for surgical and anesthesia team to give during the procedure.&#xD;
      Patients assigned to hTXA group will receive 50mg/kg IV TXA loading dose with a 5mg/kg/hr&#xD;
      maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.&#xD;
      Patients assigned to lTXA group will receive 20mg/kg IV TXA loading dose with a 5mg/kg/hr&#xD;
      maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.&#xD;
      Patients assigned to cTXA group will received 20mg/kg V TXA loading dose with a 5mg/kg/hr&#xD;
      maintenance dose, and 2g topical TXA poured over 5 minutes at the would prior to closure.&#xD;
      Otherwise, the patient, surgeon, and anesthesiologist in the case will be blinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Patients will be assigned randomly using a computer-generated table of numbers to one of the three groups:&#xD;
High Dose Intravenous TXA (hTXA group)&#xD;
Low Dose Intravenous TXA (lTXA group)&#xD;
Combined Intravenous and Topical TXA group (cTXA group).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The patient, surgeon, and anesthesiologist in the case will be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hematocrit level</measure>
    <time_frame>Baseline and Post-operative day 1, 2 and 3</time_frame>
    <description>The amount of post-operative blood loss during the first 24, 48 and 72 hours in patients undergoing multilevel spine surgery. Specifically, the hematocrit number difference between baseline and post-operative day 1, 2 and 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative drain output</measure>
    <time_frame>Post-operative day 1, 2 and 3</time_frame>
    <description>The amount of post-operative drain output (ml) during the first 24, 48 and 72 hours in patients undergoing multilevel spine surgery.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Spine Surgery</condition>
  <condition>Back Pain</condition>
  <arm_group>
    <arm_group_label>High Dose Intravenous TXA (hTXA group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to hTXA group will receive 50mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Intravenous TXA (lTXA group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to lTXA group will receive 20mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Intravenous and Topical TXA group (cTXA group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to cTXA group will received 20mg/kg V TXA loading dose with a 5mg/kg/hr maintenance dose, and 2g topical TXA poured over 5 minutes at the would prior to closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Tranexamic acid</intervention_name>
    <description>50mg/kg IV TXA</description>
    <arm_group_label>High Dose Intravenous TXA (hTXA group)</arm_group_label>
    <other_name>hTXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Tranexamic acid</intervention_name>
    <description>20mg/kg IV TXA</description>
    <arm_group_label>Combined Intravenous and Topical TXA group (cTXA group)</arm_group_label>
    <arm_group_label>Low Dose Intravenous TXA (lTXA group)</arm_group_label>
    <other_name>lTXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid Topical</intervention_name>
    <description>2g topical TXA</description>
    <arm_group_label>Combined Intravenous and Topical TXA group (cTXA group)</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline poured on wound</description>
    <arm_group_label>High Dose Intravenous TXA (hTXA group)</arm_group_label>
    <arm_group_label>Low Dose Intravenous TXA (lTXA group)</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18-80 years old&#xD;
&#xD;
          -  Undergo major multilevel spine surgery (2-8 levels)&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA class V&#xD;
&#xD;
          -  Urgent or emergent surgery,&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Patients with known coagulopathy disorder, hx of thromboembolic event &lt;1 year, renal&#xD;
             insufficiency, hepatic dysfunction, serious cardiac disease&#xD;
&#xD;
          -  Patients with known allergy to TXA or receiving antiplatelet and/or anticoagulant&#xD;
             drugs&#xD;
&#xD;
          -  Religious or other belief that limit blood transfusion,&#xD;
&#xD;
          -  Surgery duration more than 6 hours&#xD;
&#xD;
          -  Patient refusal or inability to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Lai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai West and Morningside Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenghao Fang, M.D.</last_name>
    <phone>434-326-8499</phone>
    <email>shenghao.fang@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Poonam Pai, M.D.</last_name>
    <phone>347-569-4816</phone>
    <email>Poonam.PaiBantwalHebbalasankatte@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mount Sinai West Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shenghao Fang, M.D.</last_name>
      <phone>434-326-8499</phone>
      <email>shenghao.fang@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Poonam Pai, M.D.</last_name>
      <phone>347-569-4816</phone>
      <email>Poonam.PaiBantwalHebbalasankatte@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yan Lai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>May 15, 2021</last_update_submitted>
  <last_update_submitted_qc>May 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Yan Lai</investigator_full_name>
    <investigator_title>Assistant Professor, Anesthesiology, Perioperative &amp; Pain Medicine</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>Spine surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

